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Abstract
Background: A defective skin barrier and bacterial colonization are two important factors in maintenance and
progression of atopic dermatitis and chronic allergic/irritant hand dermatitis. A water-based lipid delivery system
containing physiologic lipids was previously shown to be a useful adjunct in the treatment of hand dermatitis.
We tested the ability of this formulation to penetrate into the viable epidermis and in addition assessed its antibacterial
properties.
Methods: Epidermal penetration of the product was assessed by fluorescence microscopy. Recovery of Escherichia coli
and Staphylococcus aureus MRSA from skin treated with Neosalus® foam was quantified.
Results: Components of Neosalus® penetrated the stratum corneum and were distributed throughout the viable
epidermis. Neosalus® significantly decreased recovery of both Staphylococcus aureus and Escherichia coli from the
skin surface.
Conclusions: The ability of components of Neosalus® to be taken up into the viable epidermis and potentially
made available for incorporation into the barrier lipids, combined with antibacterial properties, indicate that this
formulation may be valuable not only in chronic hand dermatitis, but also in various other forms of dermatitis.
Trial registration: Current Controlled Trials ISRCTN18191379, 28/12/2018, retrospectively registered.
Keywords: Skin barrier, Epidermis, Penetration, Fatty acids, Antimicrobial, Staphylococcus aureus, Escherichia coli,
Dermatitis, Physiological lipids
Background
Research continues to reaffirm the important role of the
epidermal barrier in maintaining cutaneous health and
implicates barrier dysfunction in the pathogenesis of
contact dermatitis, ichthyosis, psoriasis, atopic dermatitis
[1], and in allergic and irritant contact dermatitis [2, 3].
Barrier dysfunction is linked to increased transepidermal
water loss and decreased hydration in pathological dry
skin [4] . Barrier dysfunction facilitates secondary infection
by bacteria, viruses, and fungi [5]. Staphylococcus aureus is
increasingly implicated as a factor in the pathogenesis of
atopic dermatitis [6]. The pooled prevalence of Staphylococ-
cus aureus colonization of atopic eczema patients was 70%
for lesional skin and both lesional and non-lesional skin are
commonly colonized [7–9]. Agents that combat the bar-
rier dysfunction and bacterial colonization have po-
tential therapeutic value.
The skin barrier resides principally in the stratum cor-
neum and is comprised of ceramides, cholesterol, and
free fatty acids. The skin barrier prevents the loss of
water and the penetration of foreign substances, both
pathogenic and therapeutic. The ability of substances to
cross the skin barrier depends not only on the properties
of the substance but also on the condition of the skin
[10]. Proderm Technology™ is a water-lipid-based foam
delivery system that was developed to supply active
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ingredients to the skin without disrupting the natural
skin barrier. Its unique properties are believed to be
derived from its well-defined mixture of fatty acids in
free and physically bound forms and 80% water. The
lipid components of Neosalus® include medium-chain
free fatty acids, that occur naturally in the skin. Proderm
technology confers delivery properties that are expected
to support skin barrier repair better than purely fat- or
water-based formulations. Other ingredients in Neosalus®
include glycerin and dimethicone. Glycerin is both hu-
mectant, increasing moisture in the stratum corneum
by attracting water from the dermis and the environment,
and emollient, affecting epidermal biomechanics by in-
creasing hydration [11]. Unmodified silicones, such as
dimethicone, remain on or near the skin surface, as their
molecules are too large to penetrate the epidermis, result-
ing in a barrier to moisture loss and protection against
allergens and irritants [11].
The topical delivery of therapeutic agents into the epider-
mis requires sufficient penetration of the stratum corneum
to the viable epidermis below. Accordingly, “enhancers” are
sometimes used to optimize penetration. However, while
enhancing penetration, these agents tend to disrupt the
cutaneous barrier and may cause irritation and increase
skin sensitivity. Thus, the ideal formulation for topical drug
delivery should be one that is capable of solubilizing both
hydrophilic and lipophilic substances and enhances uptake
without damaging the skin or the skin barrier [12]. Perme-
ability is governed by hydrophobic and hydrophilic chan-
nels (Fig. 1, [13]). The majority of skin surface lipids are
segregated into crystalline/gel domains bordered by “grain
borders” where lipids exist in a fluid, crystalline state. The
fluid character of this area permits the diffusion of lipid and
hydrophobic molecules through the system on downhill
gradients [12]. If the lipid content decreases, the “gate
keeper” function of the barrier becomes compromised and
water loss increases, leading to dry irritated skin. The Pro-
derm water-lipid-based foam exhibits a distribution of
water and free fatty acids; presents in anionic (hydrophilic)
and neutral (hydrophobic) form (U.S. Patent 5,993,830).
Previous studies have shown the benefit of topical skin
protectants using Proderm technology to diminish oc-
cupational and home exposure to irritants and allergens
[14, 15]. The studies here were performed to test the
ability of Neosalus® to penetrate into the viable epider-
mis and to test its antimicrobial properties; properties
expected to underlie the therapeutic efficacy seen.
Methods
Structural characterization of Neosalus®
Neosalus foam was investigated by means of light mi-
croscopy and electron microscopy. Electron micrographs
Fig. 1 Hydrophobic and hydrophilic regions of the intercellular domains: The water-lipid nature of Neosalus™ is expected to support skin barrier
repair better than purely fat- or water-based formulations. Adapted from Escobar-Chavez et al. 2012 [13]
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were generated through the cryo-Transmission Electron
Microscope Technique in which a thin film of sample is
vitrified and transmitted by electrons. The method of
cTEM has been described in detail elsewhere [16].
Penetration of fatty acids associated with Neosalus® into
viable epidermis
To measure the penetration of the physiological free fatty
acids associated with Neosalus® foam, fluorescent-labeled
Fig. 2 Visualization of Neosalus and its penetration into epidermis. a The foam exhibits a distribution of water and free fatty acids; which are
present in anionic (hydrophilic) and neutral (hydrophobic) form. b, c Light micrographs of foam showing the structure of the foam with its liquid
layers between gas (propellant) cavities. d Structures within foam are less than 1 μm (cTEM). e Normal untreated skin (H&E). f Untreated normal
skin shows minimal fluorescence. g Fluorescence seen in the stratum corneum of skin treated with fluorescent-labeled petrolatum. h Fluorescence
seen in the stratum corneum of skin treated with fluorescent-labeled dimethicone. i, j Skin treated with fluorescent-labeled Neosalus®
shows fluorescence throughout the stratum corneum and epidermis. SC: stratum corneum, E: epidermis, D: dermis, * autofluorescence of
collagen fibers
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medium-chain fatty acid 4,4-Difluoro-5-(2-Thienyl)-4-Bor-
a-3a,4a-Diaza-s-Indacene-3-Dodecanoic Acid (Bodipy™, Mo-
lecular Probes) was added in trace amounts to the foam
delivery system to travel with its fatty acid content. Similarly,
tracer was added to dimethicone and petrolatum as controls.
In previous studies, petrolatum was not observed to pene-
trate into the viable epidermis [17]. Full-thickness murine
skin biopsies (hr mice, The Jackson Laboratory) were taken
2 h after application of the test substances (mice were not
scarified), as in previous similar studies from others [18].
Samples were counterstained with a nuclear dye (DAPI,
blue) and fluorescence microscopy (Axio Plan Z, Carl Zeiss
Inc., Thornwood, NY) was used to determine the location of
the test substances 2 h after application. These studies were
performed with approval from and following the guidelines
of our Institutional animal care and use facility (IACUC).
Antimicrobial effects of Neosalus®
Institutional Review Board approval was obtained for this
study and appropriate informed consent was obtained
from all research participants (Gallatin Institutional Re-
view Board-Approved Protocol #090426–150). Twenty
healthy subjects were evaluated to determine the anti-
microbial efficacy of the compound formulation. Recover-
ies of Escherichia coli (ATCC #11229) and Staphylococcus
aureus MRSA (ATCC #33593) populations from the skin
of the treated forearms of ten subjects per bacterial species
were compared to recoveries from the skin of their un-
treated (control) forearms. After each subject had com-
pleted a 7-day restriction period (no solvents, detergents,
tanning, or swimming) 1ml of the microbial suspension
was applied to the skin of a randomly assigned forearm of
each subject. The subject’s contralateral forearm served as
an untreated control, receiving no treatment of any kind.
Four sites were delineated on the skin of each forearm,
and 10min following product application, the sites were
exposed to the randomly assigned challenge suspension
for contact times of 5min, 10min, 20min, and 40min.
Microbial suspensions were recovered from each site by
cylinder sampling and then skin sites decontaminated
with 70% IPA.
Duplicate spiral plates or duplicate spread plates were
prepared from cylinder samples (I0° dilution) on MacConkey
Agar (MAC) for Escherichia coli (ATCC #11229) and Hardy
Chrom Staph aureus (CHROM) for Staphylococcus aureus
aureus (ATCC #33593). These were incubated at 30° ± 2 °C
for 48 h and at 35° ± 2 °C for 24 h, respectively, or until suffi-
cient growth was observed. Colonies were counted and data
recorded using the Q-Count plate counting system or
equivalent.
To prepare the microbial suspensions, sterile tubes of
Tryptic Soy Broth (TSB) were inoculated from cryogenic
stock cultures or lyophilized vials containing Escherichia
coli (ATCC # ll229) and Staphylococcus aureus MRSA
{ATCC #33593). Cultures were incubated at 30° ± 2 °C
for 24 h. Immediately prior to the procedure, cultures were
transferred from Tryptic Soy Agar to Phosphate Buffer
Solution (PBS) and diluted to 1.0 × 109 CFU/mL.
Results
Neosalus® water-lipid-based foam penetrates into the
epidermis
The Proderm water-lipid-based foam exhibits a distribu-
tion of water and free fatty acids; which are present in
anionic (hydrophilic) and neutral (hydrophobic) form
(Fig. 2a). The foam consists of gas cavities surrounded
by lipid lamellae (Fig. 2b,c). Within the lamellae, struc-
tures are present that are smaller than a micrometer
(Fig. 2d). It was hypothesized that physiological lipids in
Neosalus® would penetrate into the viable epidermis
while dimethicone and petrolatum would remain on the
skin surface as a protective barrier. To measure the
penetration of physiological lipids in Neosalus® foam,
fluorescent-labeled fatty acid (Bodipy, Molecular Probes)
Fig. 3 Antibacterial properties of Neosalus®. a Mean Log10 Colony Counts of Staphylococcus aureus recovered from skin treated with Neosalus® or
untreated skin. b Mean Log10 Colony Counts of Escherichia coli recovered from skin treated with Neosalus® or untreated skin
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was added in trace amounts to the foam delivery system
to mark its fatty acid content. The tracer was also added
to dimethicone and petrolatum as controls. The foam,
dimethicone, and petrolatum, were applied to the skin
and biopsy samples taken 2 h after application. Fluores-
cence microscopy was used to determine the degree of
penetration and location of the test substances. Fluores-
cence microscopy of untreated normal skin showed min-
imal fluorescence (Fig. 2e, f ). While petrolatum (Fig. 2g)
and dimethicone (Fig. 2h) showed strong fluorescence
only in the stratum corneum, components of Neosalus®
penetrated the stratum corneum and were distributed
throughout the viable epidermis, as demonstrated by
bright fluorescence (Fig. 2i, j). Thus the fluorescent free
fatty acids in Neosalus® were delivered to the viable epi-
dermis. These lipids, as previously shown, are available
as a source of lipids for de novo barrier formation [18].
Antimicrobial properties of Neosalus
A clinical study was performed to evaluate the antimicro-
bial properties of Neosalus® (Fig. 3, Tables 1 and 2). Twenty
patients underwent application of Neosalus to one forearm
while the other forearm was used as an untreated control.
Ten minutes after product application, the sites were
exposed to either Staphylococcus aureus or Escherichia
coli, for contact times of 5, 10, 20, and 40 min, and then
skin surface bacteria collected and cultured. The Neo-
salus® treated forearm showed significantly decreased
recovery of Staphylococcus aureus at 10 min, with
eradication of bacteria after 40 min (Fig. 3a). The Neo-
salus® treated forearm showed eradication of Escheri-
chia coli at 20 min (Fig. 3b). Thus the product showed
evidence of potential antibacterial properties.
Discussion
Frustration with therapy for dermatitis is common among
both treating physicians and affected patients. Numerous
therapies are effective for acute management of dermatitis,
quell inflammation, and improve symptoms. Frustration
grows as patients taper and withdraw topical corticoste-
roids and dermatitis recurs. In recent years “barrier-repair”
creams, topical skin protectants, and other moisturizing
formulations intended to forestall dermatitis recurrence
have helped prolong clearance while decreasing patients’
exposure to topical corticosteroids. Understanding the
mechanisms by which various agents aid in barrier repair,
decrease colonization, and are anti-inflammatory will allow
us to continue to improve formulations that can provide
key therapeutic adjuncts in the treatment of dermatitis.
Previous studies have shown the benefit of topical skin
protectants using Proderm technology [17, 18]. Underlying
the therapeutic efficacy, here we show that components of
the water-lipid-based delivery system, Neosalus®, can
effectively penetrate into the viable epidermis. The free
fatty acids in Proderm could penetrate the stratum cor-
neum and be distributed throughout the viable epidermis.
Table 1 Mean Log10 Colony Counts of Staphylococcus aureus recovered from treated vs. untreated skin
Treatment Sample Time Sample Size Mean Standard Deviation 95% Confidence Interval p value
Test Product 5 Minutes 10 4.52 0.17 4.39 to 4.64 0.172
Untreated 10 4.61 0.12 4.53 to 4.70
Test Product 10 Minutes 10 2.68 2.00 1.25 to 4.11 0.014
Untreated 10 4.60 0.11 4.52 to 4.68
Test Product 20 Minutes 10 0.89 1.83 −0.42 to 2.20 0.000
Untreated 10 4.05 1.43 3.03 to 5.08
Test Product 40 Minutes 10 0.00 0.00 0.00 to 0.00 0.000
Untreated 10 4.52 0.16 4.40 to 4.63
Table 2 Mean Log10 Colony Counts of Escherichia coli recovered from treated vs. untreated skin
Treatment Sample Time Sample Size Mean Standard Deviation 95% Confidence Interval p value
Test Product 5 Minutes 10 3.70 1.36 2.73 to 4.67 0.648
Untreated 10 3.91 0.41 3.62 to 4.20
Test Product 10 Minutes 10 2.65 1.71 1.43 to 3.87 0.166
Untreated 10 3.47 0.24 3.30 to 3.65
Test Product 20 Minutes 10 0.00 0.00 0.00 to 0.00 0.000
Untreated 10 3.25 0.35 3.00 to 3.50
Test Product 40 Minutes 10 0.03 0.11 −0.04 to 0.11 0.000
Untreated 10 3.06 0.32 2.83 to 3.29
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While many components of Neosalus could contribute
to antibacterial properties, long chain fatty acids are
known to be bactericidal or/and inhibit bacterial growth
[19–21]. Also, additionally or alternatively, barrier repair
could be an indirect mechanism for antibacterial proper-
ties. Antibacterial properties would constitute an excit-
ing benefit for patients with atopic dermatitis who are
mostly colonized by Staphylococcus aureus. Importantly,
a limitation of this work is that long-term benefits to
skin microflora have not yet been investigated and this
will be important.
Topical steroids are commonly used for the treatment
of dermatitis, but they are associated with many side ef-
fects, including skin atrophy. An effective barrier-repair
and protection foam is important for acute and chronic
treatment of dermatitis and for some may be useful as
an alternative to topical steroids and immunomodulators.
Furthermore, barrier maintenance properties and bacteri-
cidal properties may help prevent flares of dermatitis.
Conclusions
Constituents of Neosalus® are taken up into the viable
epidermis making them available for lipid incorporation
into the barrier. These studies also indicate that Neosalus®
has possible antibacterial properties. These properties sug-
gest that this formulation may be valuable not only in
chronic hand dermatitis, but also in various other forms
of dermatitis.
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